Bridging science and health policy in cardiovascular disease: focus on lipid management: A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention – Health Policy, in Venice, Italy, on 25 October, 2008
Introduction
[Volpe M.]
Despite remarkable progress in our understanding of the causes, diagnosis, and management of cardiovascular disease (CVD), strategies to prevent this potentially devastating condition remain largely unsatisfactory throughout the European Union (EU). Although variations in secular trends exist across Europe, the large and increasing incidence of CVD is largely due to poor control of traditional CVD risk factors (such as hypertension and hypercholesterolaemia), the growing incidence of obesity and diabetes in adults and young people, and the sedentary lifestyle and poor dietary habits of modern society.
The progressive and marked increase in the incidence of CVD is a matter of intense and growing concern among many regulators and professionals involved in maintaining and promoting public health. Current health care systems dedicated to acute CVD care (such as coronary care, stroke, and rehabilitation units, intensive care units (ICUs), and specialised outpatient clinics) could quickly become overwhelmed by the growing number of patients requiring prolonged intensive care and assistance. Indeed, disease projections and demographic trends in the European region combined with the routine difficulties admitting patients to ICUs suggest that the health care system may already be imperilled in some countries. In Italy, for example, about half of patients experiencing sudden cardiac arrest (SCA) or acute myocardial infarction (MI) are treated outside of ICUs. In light of these trends, sustaining the advance of medical assistance in terms of the economic costs of drugs, therapeutic devices, diagnostic and interventional technologies, and follow-up programmes will be challenging.
[Wood D.]
It is clear that, in the absence of effective CVD health policy, robust medical evidence and physician expertise do not necessarily translate into high standards of preventive care. In recent years, therefore, European physicians have become more actively engaged in CVD health policy development, as evidenced by the development of the Joint European Societies Prevention Guidelines [1, 2, 3, 4 and the creation of the European Heart Health Charter (EHHC) [5] launched in Brussels on 12 June, 2007. While acknowledging and respecting individual country autonomy, EHHC advocates a unified approach to CV health, promoting the translation, adaptation, and dissemination of CVD prevention guidelines. In particular, the EHHC called for establishment of national strategies for the detection and management of patients at high risk of CVD and the prevention and care of those with established CVD. The overall objective is to bridge the treatment gap between what is recommended and what is achieved in daily practice regarding CVD prevention.
To help support the increasing activities of the EU and national parliaments with respect to CVD health policy (particularly as it relates to lipids), a panel of European experts in CVD management, economics, and health policy, convened at an international symposium on Bridging Science and Health Policy in Cardiovascular Disease: Focus on Lipid Management, in Venice, Italy, on October 25, 2008, to review and discuss the following issues:
- •
The clinical and socioeconomic impact of CVD in the EU
- •
The impact of lipid-lowering strategies (particularly LDL-C reduction) on CVD outcomes
- •
Targeted “high-risk” versus population approaches to reduce CVD risk
- •
The cost-effectiveness of lipid-lowering strategies and their potential role in improving long-term financial health care sustainability
- •
The barriers and incentives to CVD prevention
- •
Overcoming barriers to proper lipid management and implementing strategies to improve CVD prevention: the Italian experience.
This article serves as a compilation of the broad range of material presented and discussed during the meeting and summarises the conclusions made.
Section snippets
Global and European burden of CVD
[Volpe M.]
The clinical and socioeconomic impact of CVD is substantial. According to World Health Organisation (WHO) 2004 statistics, CVD represents the number one cause of death worldwide, accounting for 29% of total mortality (Fig. 1) [6]. In Europe, CVD represents the main cause of morbidity, mortality, and hospitalisation [7, 8, 9. CVD is the largest contributor to the European burden of disease in terms of mortality – considerably larger than infectious and parasitic diseases, malignant
Economic burden of CVD
[Volpe M.]
In the US in 2006, the cost of CVD was estimated to be $ 368 billion (two-thirds of the overall in-hospital medical assistance cost); a 25% increase over the next 25 years would result in CVD costs increasing to $ 550 billion [13]. In Italy, the effective gross cost of the intra-hospital phase of acute MI could be around € 6000 per patient (€ 720 million per year); a 25% increase in MI over the next 25 years (without considering the costs related to rehabilitation, leave of absence
Clinical outcome benefits of lowering LDL-C
[Atella V.]
Several key factors contribute to CVD, including age, high blood pressure (BP), smoking, high cholesterol levels, high body mass index (BMI), obesity, and diabetes. The median age in most member states of the EU is now over 30 years (Italy is the highest with 41.6 years). By 2020, 20% of people in Europe will be over 60 years and more than 5% will be over the age of 80 years. Obesity and diabetes are estimated to be 30 million in 2020, with obesity and overweight, in particular,
Targeted “high-risk” versus population approaches to reduce CVD risk
[Critchley J.]
Public policies outside of the health service play a major role in influencing public health, generally by facilitating (or hindering) healthier choices among the population. The role of these population interventions for reducing CVD (primary prevention) compared with targeted “high risk” approaches has been much debated.
Cost-effectiveness of lipid-lowering therapy
[Lindgren P.]
The introduction of statins led to increased interest in economic aspects of lipid-lowering therapy. Since statins were perceived as effective but potentially very costly, a need existed to assess the economic consequences of this class of drug. Initially this was achieved through prediction models (such as using Framingham risk equations) but the completion of end-point trials (starting with the Scandinavian Simvastatin Survival Study (4S)) led to economic evaluations based on
Better lipid-lowering therapy improves long-term financial health care sustainability: a simulation model
[Atella V.]
Despite improvements in drug treatments and medical care over the last 25 years, CVD currently represents a major health care issue in terms of both health and economic aspects and is expected to be a growing concern for the future. Hospitalisation forecasts in Italy (based on Ministry of Health data) show that the number of patients at risk of hospitalisation for CVD due to high cholesterol levels is anticipated to increase by more than 50% over the next 30 years (assuming
Barriers and incentives to CVD prevention
[Hobbs F.D.R.]
This section serves to identify the spectrum of barriers to implementing CVD prevention (including those strategies pertaining to lipid management) as well consider potential incentives to overcome these barriers.
Overcoming barriers to proper lipid management: lessons from Italy
[Vanuzzo D.]
Overcoming barriers to proper lipid management in country-specific health organisations will require revising the legislative and administrative policy objectives at the EU, national, and regional levels. Examples of these new objectives could be: (1) To implement national and regional cholesterol performance measures and incentives for primary care physicians to screen high risk patients and achieve cholesterol target levels in these patients; (2) To identify and eliminate
Strategies and interventions to improve CV prevention: the Italian experience
[Volpe M.]
CVD is expected to have a substantial clinical and socioeconomic impact in Italy in the next few years, potentially threatening the sustainability of the entire national health care system [9]. To enhance the level of attention on interventional strategies for improving CV prevention in Italy, consensus document or White Paper was developed [9].
Speaker Panel discussion
After reviewing the facts about CVD and barriers to achieving widespread improvements in lipid control and CVD prevention, the panel members, under the direction of the meeting co-chairmen (see layout of the Session, page 21), identified and discussed several aspirational and achievable goals or targets that could potentially improve the health of all nations within the EU. These key issues are summarised in Table 7) and described below.
- •
Evaluate the economic burden of disease by
Concluding remarks
[Graham I.M.]
The key priorities to improve the health of all nations within the EU with respect to lipid lowering and CVD prevention should include the following:
- •
All policy recommendations should fall within the general context of the EHHC.
- •
Multidisciplinary implementation groups that include politicians, educators, as well as physicians, need to be convened and empowered.
- •
The general public health issues of obesity and fat balance within Europe urgently need addressing.
- •
Equity of access of
References (55)
- et al.
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
Atherosclerosis
(1998) - et al.
Lipids and risk of coronary heart disease. The Framingham Study
Ann Epidemiol
(1992) - et al.
Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols
Am J Cardiol
(1980) - et al.
Lipoprotein concentrations in newborns are associated with allelic variations in their mothers
Atherosclerosis
(2004) - et al.
Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis
J Am Coll Cardiol
(2005) - et al.
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries
Clin Ther
(2008) - et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Lancet
(2003) - et al.
Lipid management in cardiovascular disease prevention guidelines: strategies and tactics for implementation
Atherosclerosis
(2008) - et al.
Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
Eur Heart J
(1994) - et al.
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)
Eur J Cardiovasc Prev Rehabil
(2003)
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)
Eur J Cardiovasc Prev Rehabil
European Heart Health Charter
The global burden of disease: 2004 update
The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions
Circulation
The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)
Circulation
2008 White Paper for implementing strategies and interventions for cardiovascular prevention in Italy
High Blood Pressure & Cardiovascular Prevent
Projections of mortality and burden of disease, 2002-2030
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents
Circulation
Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Circulation
Economic burden of cardiovascular diseases in the enlarged European Union
Eur Heart J
FP7 Seventh Framework Programme
The relation between funding by the National Institutes of Health and the burden of disease
N Engl J Med
Cost of cardiovascular diseases in the United Kingdom
Heart
Lipoproteins and atherogenesis. Current concepts
JAMA
Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
JAMA
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
BMJ
Cited by (17)
Implementation of cardiovascular secondary prevention guidelines in clinical practice: A nationwide survey in Italy
2012, Nutrition, Metabolism and Cardiovascular DiseasesCitation Excerpt :These findings clearly indicate that drug prescription, although appropriate, is not adequately targeted by referring physicians in the majority of high-risk patients. Thus, despite recently reported improvement [8], inadequacy of lipid control continues to represent a major challenge in cardiovascular health policy, accounting for a sizeable number of unprevented cardiovascular events [2,3,9,10]. In addition to inadequate lipid control, 20% of patients were obese and only 35% had a BMI within normal ranges.
Translating cholesterol guidelines into primary care practice: A multimodal cluster randomized trial
2011, Annals of Family MedicineCitation Excerpt :Despite the publication of these guidelines in 2001 and an update in 2004,2,3 there continues to be large variations in clinical practice,4,5 and it is estimated that 40 million Americans have hyperlipidemia treated suboptimally.6 This problem of underscreening and undertreatment of dyslipidemia is also true for Canada, Britain, Australia, and other European Union countries.7–14 Potential barriers to the implementation of cholesterol guidelines into clinical practice appear related to clinician knowledge, attitudes, and behaviors; patient knowledge, attitudes, and behaviors; doctor-patient communication issues; and system-based issues, such as economics and the lack of organized systems of care around the recognition and treatment of hyper-lipidemia.15–17
Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018
2018, Giornale Italiano di CardiologiaEthnical minorities
2018, Giornale Italiano di CardiologiaThe effect of eight weeks of aquatic aerobic training on lipid profile, glucose, insulin resistance and apoprotein A and B in overweight postmenopausal women
2017, Iranian Journal of Obstetrics, Gynecology and Infertility